|Articles|July 29, 2013
Mechanism of Action: Afatinib (BIBW 2992)
Afatinib is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Advertisement
Afatinib (Gilotrif), previously known as BIBW 2992, is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma
3
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
4
Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL Trial
5